Trial Profile
Randomised, Sequential, Cross-over Trial Assessing PK and PD Responses After Micro-doses of ZP4207 Administered s.c. to Patients With T1D Under eu- and Hypoglycemic Conditions and With Reference to Freshly Reconstituted Lyophilized Glucagon
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Dasiglucagon (Primary) ; Glucagon
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Zealand Pharma
- 26 Jun 2018 Results (n=17) presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
- 23 Jun 2018 According to the Zealand Pharma media release, data from this trial will be presented at the 78th Scientific Sessions of the American Diabetes Association (ADA) 2018.
- 23 May 2017 Results published in a Zealand Pharma media release.